Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer
Regeneron is off and running with its launch of linvoseltamab in Europe. In the U.S., the company is awaiting an FDA decision after last year's rejection.
Regeneron is off and running with its launch of linvoseltamab in Europe. In the U.S., the company is awaiting an FDA decision after last year's rejection.
